Verve Therapeutics to Participate in the Guggenheim Securities SMID Cap Biotech Conference
Verve Therapeutics, Inc. (VERV)
Company Research
Source: GlobeNewswire
BOSTON, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that Sekar Kathiresan, M.D., co-founder and chief executive officer, will participate in a fireside chat at the Guggenheim Securities SMID Cap Biotech Conference on Wednesday, February 5, 2025 at 9 a.m. ET in New York. A live webcast will be available in the investor section of the company’s website at www.vervetx.com. The webcast will be archived for 90 days following the presentation. About Verve Therapeutics Verve Therapeutics, Inc. (Nasdaq: VERV) is a clinical-stage company developing a new class of genetic medicines for cardiovascular disease with the potential
Read more
Impact Snapshot
Event Time:
VERV
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VERV alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VERV alerts
High impacting Verve Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
VERV
News
- Mutated DNA Restored to Normal in Gene Therapy Advance [The New York Times]The New York Times
- Verve Therapeutics, Inc. (NASDAQ: VERV) had its price target lowered by analysts at Royal Bank of Canada from $17.00 to $15.00. They now have an "outperform" rating on the stock.MarketBeat
- Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
- Verve Therapeutics, Inc. (NASDAQ: VERV) had its price target raised by analysts at HC Wainwright from $14.00 to $15.00. They now have a "buy" rating on the stock.MarketBeat
- Verve Therapeutics Announces Pipeline Progress and Reports Fourth Quarter and Full Year 2024 Financial Results [Yahoo! Finance]Yahoo! Finance
VERV
Earnings
- 2/27/25 - Beat
VERV
Sec Filings
- 2/27/25 - Form POS
- 2/27/25 - Form S-8
- 2/27/25 - Form 10-K
- VERV's page on the SEC website